Levera 500 Tablet contains Levetiracetam 500mg, an antiepileptic medication primarily indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein 2A (SV2A), thereby stabilizing neuronal activity and preventing seizure propagation. This mechanism distinguishes it from other antiepileptic drugs, contributing to its efficacy and favorable safety profile. Levera 500 is administered orally and is well absorbed with rapid onset of action. It is often used as adjunctive therapy but may also be prescribed as monotherapy depending on clinical evaluation. Dosage should be individualized based on patient response, renal function, and tolerability, with careful titration to minimize adverse effects. Common side effects include dizziness, somnolence, headache, and fatigue, while serious adverse reactions are rare but may include mood changes and hypersensitivity reactions. Regular monitoring of clinical status and renal function is recommended during treatment. Levera 500 Tablet should be used under medical supervision, with caution advised in patients with a history of psychiatric disorders or renal impairment. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients.